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Abstract 
Introduction: The efficacy of tuberculosis (TB) treatment in Human Immunodeficiency Syndrome (HIV) co-infected patients may be 
compromised by genetic and pharmacokinetic variation in drug disposition. Rifampicin is a critical component of TB treatment. We 
investigated the influence of drug transporter gene polymorphisms on rifampicin concentrations in TB-HIV co-infected patients in Durban, 
South Africa. 
Methodology: Rifampicin concentrations were measured 2.5 hours post-dose (approximated peak, C2.5hr) in patients receiving either 450mg 
or 600mg rifampicin, randomized to either integrated or sequential antiretroviral treatment. Patients were genotyped for SLCO1B1 
(rs4149032) polymorphisms. A mixed effects regression model was fitted to assess the influence of various factors on rifampicin 
concentrations. TB recurrence rates were also estimated. 
Results: In 57 patients, median (IQR) C2.5hr was 3.6 (2.8-5.0) µg/mL. Polymorphism frequency in the SLCO1B1 (rs4149032) drug transporter 
gene was high (0.76) and was associated with low median rifampicin C2.5hr, 3.7 (2.8-5.0) µg/mL in the heterozygous and 3.4 (2.7-4.7) µg/mL 
in the homozygous variant carriers. Concentrations were also low in males (p < 0.0001) and those with low haemoglobin (p = 0.02). 
Although reinfection could not be distinguished from reactivation for the 43 patients followed post trial, the incidence of TB recurrence was 
7.1 per 100 person-years. Of the eight patients in whom TB recurred, seven had the polymorphism. 
Conclusion: Approximated peak rifampicin concentrations were well below the recommended target range of 8 to 24 μg/mL in this patient 
population with its high frequency of the SLCO1B1 (rs4149032) polymorphism. Increased rifampicin dosage may be warranted in African, 
HIV- TB co-infected patients.  
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Introduction 
In 2011 it was estimated that globally 8.7 million 
people were newly infected with TB [1]. Of these, 1.2 
million were also co-infected with HIV and most of 
these patients resided in sub-Saharan Africa [1]. In co-
infected patients, integrated treatment with anti-TB 
drugs and antiretrovirals has been shown to improve 
survival [2]. However, drug interactions, drug 
tolerability and sub-optimal tuberculosis drug 
bioavailability remain a concern [3]. In addition, the 
pharmacokinetics of anti-TB drugs are influenced by 
other factors including genetics and disease states such 
as those that compromise immunity [4-6].   
Rifampicin is a critical and potent component of 
first-line, multi-drug TB therapy because of its early 
sterilizing activity against Mycobacterium tuberculosis 
in the intensive phase and sustained activity against 
persistent bacilli throughout the continuation phase of 
TB treatment [7,8]. Metabolism is mainly hepatic, 
with up to 24% and 50% of drug excreted in the urine 
and bile unchanged respectively [9]. Rifampicin 
induces several cytochrome P450 enzymes [10] and 
hepatocellular uptake is mediated by an organic anion-
transporter polypeptide 1B1 (OAT1B1) coded for by 
the gene SLCO1B1 [11]. Polymorphisms in this gene 
influence rifampicin pharmacokinetics significantly 
and are implicated in low rifampicin exposure [6,12]. 
Anti-TB activity and development of resistance are 
linked to rifampicin concentrations [13,14] and 
rifampicin peak concentrations of 8 to 24 μg /mL are 
generally considered to be associated with optimal 
bactericidal killing and post antibiotic effect [15]. 
The purpose of this study was to assess rifampicin 
concentrations in TB-HIV co-infected patients and to 
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investigate the phenotypic and genotypic attributes 
that may influence these concentrations. 
 
Methodology 
In the ‘Starting Tuberculosis and Antiretroviral 
Therapy’ (START) trial (CAPRISA 001: 
NCT00091936) described previously, patients (n = 58) 
who had no prior history of TB, were randomized 
equally to receive integrated TB and HIV treatment (n 
= 29) or HIV treatment following the completion of 
TB treatment (n = 29) [16]. In both arms, ART 
comprised of once daily enteric-coated didanosine 
(400 mg for participants > 60 kg; 250 mg for 
participants < 60 kg), lamivudine 300mg and efavirenz 
600mg, but if > 50kg and on TB treatment, then 
efavirenz 800mg was prescribed. TB treatment was 
provided using fixed dose combination (FDC) TB 
drugs, usually for 6 months, in a directly observed 
therapy (DOT) program. In the intensive phase of TB 
treatment each FDC tablet contained: rifampicin 
120mg / isoniazid 60mg / pyrazinamide 300mg / 
ethambutol 200mg. In the continuation phase of TB 
treatment FDCs comprised rifampicin 300mg / 
isoniazid 150mg or rifampicin 150mg / isoniazid 
100mg. FDCs were dosed according to weight bands 
detailed in the TB control programme guidelines in 
effect at the time of the study. Accordingly, rifampicin 
dose was 450mg daily for five days a week in patients 
weighing < 50 kilograms (kg) or 600mg dosed daily 
five times a week in patients weighing 50 kg or more 
[16].  
Blood samples were collected from 57 patients, at 
weeks 4, 8 and 12 of TB treatment at 2.5 hours post-
dose in order to approximate peak rifampicin 
concentrations. Serum rifampicin concentrations were 
measured by tandem HPLC mass spectrometry using a 
methodology described previously [17]. The assay had 
a lower limit of quantitation of 0.1 μg/mL and inter- 
and intra-day coefficients of variation below 10%. 
DNA for the genotyping of the drug transporter gene 
coded by SLCO1B1 (rs4149032), previously shown to 
be associated with low rifampicin concentrations [12], 
was extracted from stored peripheral blood 
mononuclear cells using the Roche MagNA Pure LC 
DNA kit I (Version 17.0, Roche Diagnostics, 
Mannheim, Germany). Allelic discrimination reactions 
were performed in duplicate using a TaqMan (Applied 
Biosystems, Foster City, USA) commercial 
genotyping assay (C_1901709_10, rs4149032). Real 
Time polymerase chain reaction (RT-PCR) was 
performed on the Roche Light Cycler 480 platform 
(Roche Diagnostics, Mannheim, Germany). The final 
volume for each reaction was 25μl, consisting of 
TaqMan Genotyping Master Mix (Applied 
Biosystems, Foster City, CA, USA), 40X drug 
metabolising genotype assay mix and 10ng of genomic 
DNA. The thermal cycler conditions were as follows: 
initial step: 95°C for 10 minutes, then 50 cycles 
consisting of denature at 92°C for 15 seconds and 
anneal/extend at 60°C for 90 seconds.  
Data analysis was performed with SAS version 9.3 
(SAS Institute Inc., Cary, NC). A Mann- Whitney test 
was used to compare median rifampicin 
concentrations. A mixed effects regression model, 
suitable for repeated measures, was used to test the 
influence of variables of interest on rifampicin 
concentrations. Post-trial TB recurrence was assessed 
by determining the period of risk for TB acquisition as 
the time in follow-up from the initial successful TB 
treatment completion date up to the re-treatment date 
or the last clinical contact date available. Poisson 
approximations were used to calculate confidence 
intervals for TB recurrence rates. SLCO1B1 
(rs4049032) mutations were tested and found to be in 
Hardy-Weinberg equilibrium. A type 1 error, α = 0.05, 
was used to reject the null hypothesis.  
Ethics approval was obtained from the University 
of KwaZulu-Natal biomedical research ethics 




The median age of the 57 patients in this analysis 
was 33 years (range: 19-54). All were Black African 
and 56% were men. At baseline, mean (SD) weight 
was 57.3 (9.0) kg, BMI was 21.8 (3.6) Kg/m2, CD4 
count was 282 (153) cells/mm3 and haemoglobin was 
10.3 (1.6) g/dL.  
Median duration of TB treatment was 219 days 
(range: 181-291 days) and was similar in both the 
integrated and sequential arms. One hundred and fifty 
six rifampicin concentrations were available for 
analysis from the 57 patients. Of these, 44 patients 
contributed concentrations at three time points, 11 at 
two and two at one time point. Median (IQR) 
rifampicin concentrations were 3.6 (2.8-5.0) μg/mL 
overall and 3.5 (2.8-4.7) μg/mL and 3.7 (2.8-5.2) 
μg/mL in the integrated and sequential treatment arms 
respectively (p = 0.8). Relevant concentrations for the 
450mg and 600mg dose of rifampicin were 3.29 (1.25-
5.25) μg/mL and 4.06 (2.91-5.76) μg/mL, respectively 
(p = 0.06). Taking weight into account the rifampicin 
dosages ranged from 6.4mg/kg -13.2 mg/kg (Figure 1) 
and were similar in both arms.   
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Table 1. Mixed effect model estimating the influence of selected variables on C2.5hr rifampicin concentrations 
Variables 
(N = 57) 
Univariate Model Multivariate model 
 estimate SE P value  estimate SE P value 
Weight (kg) 0.01 0.02 0.84 0.01 0.02 0.56 
Female vs. Male 1.78 0.39 <0.0001* 2.64 0.48 <0.0001* 
Age (years) -0.01 0.03 0.65 0.05 0.03 0.09 
Non –Smoker vs. Smoker (status at baseline) 1.14 0.62 0.07 0.63 0.52 0.23 
Dose/Weight (mg/kg) 0.09 0.16 0.56 0.33 0.16 0.04* 
SLCO1B1 (rs4149032) allele       
Heterozygous vs. Wild type -1.66 0.97 0.09 -1.45 0.83 0.09 
Homozygous vs. Wild type -1.63 0.93 0.09 -1.71 0.79 0.04* 
Haemoglobin (g/dL) -0.12 0.13 0.34 0.32 0.13 0.02* 
CD4 Count (per 50 cell/mm3 increase) -0.04 0.07 0.59 0.019 0.07 0.76 
TB recurrence vs. sustained cure -0.10 0.67 0.88 0.10 0.56 0.86 
*p<0.05, statistically significant 
Figure 1. Graph of approximated peak rifampicin concentrations 
in relation to dose (mg/kg) for the integrated and sequential 
arms. 
Figure 2. Graph of approximated peak rifampicin 
concentrations and gender. The median concentration is 
denoted by the bar. 
Figure 3. Graph of approximated peak rifampicin concentrations 
and SLCO1B1 (rs4149032) allele frequencies. The median and 
interquartile range are represented by the bar and whiskers. 
Figure 4. Graph of approximated peak rifampicin concentrations, 
SLCO1B1 (rs4149032) genotype and gender. The median 
concentration is denoted by the bar. 
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Women had a median rifampicin concentration of 
4.1 (3.3-5.3) μg/mL compared to 3.2 (2.6-4.1) μg/mL 
in men (p = 0.006) as shown in Figure 2.  
Allele frequency for SLCO1B1 (rs4149032) 
polymorphism was 0.76. Fifty seven percent (n = 33) 
of patients were homozygous for the variant allele, 
while 38% (n = 21) were heterozygous and 5% (n = 3) 
were homozygous for the common allele of the gene 
(wild type). The median (IQR) rifampicin 
concentrations were 3.4 (2.7-4.7) μg/mL, 3.7 (2.8-5.0) 
μg/mL and 5.3 (3.8-6.7) μg/mL respectively (Figure 
3). Figure 4 shows the relationship between rifampicin 
concentrations, genotype and gender. 
Predictors thought to influence rifampicin 
concentrations were tested in both univariate and 
multivariate models for repeated measures (Table 1). 
Male gender (p < 0.0001), haemoglobin per unit 
increase (p = 0.02) and homozygous variant allele 
carriers were associated with lower rifampicin 
concentrations. Higher dose per kilogram of body 
weight was associated with a higher rifampicin 
concentration (p = 0.04), but weight alone, smoking 
status, CD4 count and later TB recurrence were not 
predictive of lower rifampicin concentrations. 
Patient outcomes, during and after the trial, are 
summarized in Figure 5. Sputum cultures were 
available at month two for only 55 of the 57 patients 
and 47 (85.4%) of these were found to be negative. 
Among the eight patients who were sputum positive, 
two had primary MDR TB and remained sputum 
positive throughout the study. Three subsequently 
developed recurrent TB, after completion of treatment, 
and the remaining three went on to become sputum 
negative at 6 months. 
Fifty one of the 57 patients completed TB 
treatment and 49 of them were sputum culture 
negative at 6 months. The two with MDR TB who 
remained sputum positive are mentioned above. Of the 
58 patients originally enrolled, four had died (one of 
unknown cause prior to contributing a drug level, one 
suicide, one embolism and one death was TB-related) 
and three had been lost to follow up.  
Forty three patients continued receiving 
antiretroviral treatment at our CAPRISA clinic; eight 
(18.6%) of them developed recurrent TB during 113.1 
person years of follow-up. The TB recurrence rate was 
7.1 (95% CI: 3.1-13.9) cases per 100 person-years. 
The median time from completion of TB treatment to 
the post-trial diagnosis of recurrent TB was 639 days 
(range 56 – 1832 days). Of the eight patients in whom 
TB recurred, seven had the polymorphism and of these 
six were homozygous carriers of the variant allele.  
TB treatment interruptions were investigated and 
durations of greater than 14 days occurred in two 
participants, both during the continuation phase of TB 
treatment. One patient, who was incarcerated and 
missed 19 days of treatment, was among the eight who 
had recurrent TB after treatment was completed. The 
other, the patient who died of TB, had missed a 
cumulative 43 days of treatment. 
 
Discussion 
The bactericidal activity of rifampicin is 
concentration dependent [18]. Ratios of both Cmax to 
MIC and AUC to MIC are important [5, 8], and a Cmax 
target range of 8 to 24 μg /mL is recommended for 
optimal bactericidal activity and post-antibiotic effect 
[15]. Accordingly, the fact that our 57 patients had a 
median C2.5hr of 3.6 µg/ml, with none being > 8 µg/ml, 
is a cause for concern. As expected, median rifampicin 
concentrations where similar when HIV treatment was 
integrated or sequential.  
Various factors could have contributed to our low 
rifampicin concentrations in both arms, one being the 
routine use of FDCs in South Africa, where 
formulation factors could affect bioavailability [19]. 
Consistent with the findings of earlier studies, male 
gender was associated with lower concentrations [20, 
21] as was low haemoglobin, which has previously 
been linked to poorer TB outcomes [22]. HIV co-
infection may also be a factor; in a group of 34 co-
infected patients receiving 600mg of rifampicin daily, 
Figure 5. Patient outcomes post enrollment. 
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where reported Cmax concentrations of < 8µg/ml 
occurred in 77% of cases and 35% of these 
concentrations were < 4µg/ml. Overall the median was 
5.4 µg/ml [5]. Similarly, in 155 co-infected patients 
from Botswana, median Cmax values (at 2 hours) were 
4.4 and 5.7 µg/ml in those with CD4 counts of less 
than and greater than 200 cells/µL respectively [23]. 
We found no association between CD4 count at 
baseline and rifampicin concentrations sampled.  
We found the polymorphism frequency for the 
drug transporter gene SLCO1B1 (rs4149032) to be 
high in our patients (0.76) and mutations in this gene 
were associated with low rifampicin concentrations. 
Our allelic frequencies and related associations with 
low concentrations are very similar to those reported 
in Cape Town by Chigutsa et al. who found an allelic 
frequency of 0.70 and rifampicin Cmax < 8µ/ml in 69% 
of their patients [12]. Evidence for the importance of 
the SLCO1B1 drug transporter gene in determining 
rifampicin exposure, also comes from a study by 
Weiner et al. These authors studied 
SLCO1B1 463C→A and found that patients with this 
polymorphism had a 36% decrease in AUC0-24. Their 
African patients had the highest frequency of this 
polymorphism [15] in contrast to the Cape Town study 
where the 463C→A polymorphism was infrequent and 
did not appear to associated with rs4149032 [12]. 
Limitations of the current analysis include the 
small sample size and the inability to assess for 
delayed absorption due to the single time point 
sampling, although from the literature, sampling 2-3 
hours post administration is generally when peak 
rifampicin concentrations are reached. Moreover, in 
more than one occasion the same patient was sampled.  
We were also unable to distinguish between 
reinfection and reactivation, as this was not part of the 
study design. However, TB recurred in 18.6% of 
patients who had been confirmed sputum negative at 
the end of TB treatment. Our recurrence rate of 7.1 per 
100 person-years was comparable with the figure of 
8.4 per 100 person-years in similar patients in a 
Ugandan study [24], although rifampicin 
concentrations were not measured in that study. While 
it was not possible to directly attribute recurrence in 
our study to low rifampicin concentrations, lower TB 
drug concentrations have previously been postulated to 
be associated with poorer treatment outcomes 
[8,15,23]. Of the 8 patients in whom TB recurred after 
treatment was completed, 87.5% had the 
polymorphism and 75% were homozygous for the 
variant allele. Furthermore, the TB related death was 
also in a patient homozygous for the variant allele in 
whom low rifampicin concentrations had been 
measured. The two cases of MDR TB were primary 
and only diagnosed retrospectively and hence were 
unrelated to treatment and rifampicin concentrations. 
Chigutsa et al., who considered the SLOC1B1 
(rs4149032) polymorphism an important determinant 
of the low rifampicin concentrations in African 
patients, recommended an increase to the current 
standard daily dose. After model simulations, they 
demonstrated that a daily dose increment of 150mg 
would produce concentrations similar to those 
achieved in wild type individuals and would reduce 
the percentage of patients with concentrations below < 
8µ/ml by 50% [12]. In support of a dose increase is a 
recent 14 day study where rifampicin doses of 10, 20, 
25 and 30mg/kg produced mean Cmax concentrations of 
7.4, 21.6, 25.1 and 33.1 mg/L in adult smear positive 
TB patients [25]. Evidence from this trial suggested 
that higher doses of rifampicin, even up to 35mg/kg, 
appear to be well tolerated, safe and exhibit optimal 
drug exposure [25]. 
 
Conclusion 
Our patient cohort of TB-HIV co-infected Black 
South African patients exhibited both extremely low 
rifampicin concentrations and a high frequency of 
polymorphisms in the SLCO1B1 (rs4149032) drug 
transporter gene. Further research on the possible need 
for increased rifampicin dosage and a more 
comprehensive exploration of the role of 
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